Investor Relations

Investor FAQ In Relation to Merger

Download PDF

 

Corporate Profile

Ocugen is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases.

Copyright West LLC. Minimum 15 minutes delayed.

Contact Information

Kelly Beck, MBA, SPHR, SHRM-SCP, PMP
VP, Investor Relations & Administration
Phone: +1 (484) 328-4698
kelly.beck@ocugen.com

Receive Email Alerts Email alert icon

Sign up here to receive email alerts whenever Ocugen, Inc. posts new information on the site. Just enter your email address and click Submit.